BRIEF published on 03/14/2025 at 15:21, 8 months 21 days ago JP Morgan Chase Reduces Stake in ABIVAX Actions Abivax Regulation Threshold Crossing JP Morgan Chase
BRIEF published on 03/13/2025 at 12:43, 8 months 23 days ago JP Morgan Crosses Threshold in ABIVAX Voting Rights Actions Abivax Threshold Crossing JP Morgan
BRIEF published on 02/25/2025 at 18:05, 9 months 7 days ago ABIVAX: Information on capital and voting rights as of January 31, 2025 Euronext Paris Share Capital Voting Rights Abivax Finances
BRIEF published on 02/21/2025 at 08:35, 9 months 12 days ago Abivax to Hold Expert Webcast on Ulcerative Colitis Abivax Obefazimod Ulcerative Colitis Clinical Trial Webcast Event
PRESS RELEASE published on 02/21/2025 at 08:30, 9 months 12 days ago Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Abivax to host Key Opinion Leader (KOL) webcast featuring Dr. David Rubin on March 17, 2025, discussing ulcerative colitis treatment landscape and ABTECT Phase 3 Trial Abivax Ulcerative Colitis Webcast ABTECT Phase 3 Trial Key Opinion Leader
BRIEF published on 02/18/2025 at 10:08, 9 months 15 days ago Crossing of threshold at ABIVAX: statement from Sofinnova Voting Rights Abivax Threshold Crossing Product Development Sofinnova Partners
BRIEF published on 01/28/2025 at 08:35, 10 months 8 days ago Abivax unveils its financial calendar for 2025 Financial Results Biotechnology Half-yearly Report Financial Calendar Abivax
PRESS RELEASE published on 01/28/2025 at 08:30, 10 months 8 days ago Abivax Publishes 2025 Financial Calendar Abivax publishes its 2025 financial calendar, detailing key financial communications throughout the year. The company is focused on developing therapies for chronic inflammatory diseases Biotechnology Abivax Therapeutics Chronic Inflammatory Diseases 2025 Financial Calendar
BRIEF published on 01/27/2025 at 18:05, 10 months 8 days ago ABIVAX: Update on shares and voting rights as of December 31, 2024 Share Capital Voting Rights Actions Abivax Financial Transparency
BRIEF published on 01/23/2025 at 22:10, 10 months 12 days ago Abivax presents seven abstracts on Obefazimod at ECCO 2025 Biotechnology Abivax Obefazimod Ulcerative Colitis ECCO Congress 2025
Published on 12/05/2025 at 14:00, 51 minutes ago Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 51 minutes ago Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange
Published on 12/05/2025 at 02:35, 12 hours 16 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 13 hours 51 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/05/2025 at 14:22, 28 minutes ago EQS-Adhoc: Jungheinrich AG: Jungheinrich expects to complete sale of its Russian subsidiary in 2026 and adjusts forecast for the 2025 financial year
Published on 12/05/2025 at 14:16, 34 minutes ago Advanced Blockchain AG: Successful Completion of Token Generation Event of Portfolio company Talisman
Published on 12/05/2025 at 14:10, 40 minutes ago The Kingdom of Saudi Arabia Launches a New Official Platform, "Saudi Properties", Ahead of the Non-Saudi Property Ownership Law
Published on 12/05/2025 at 13:45, 1 hour 5 minutes ago BingX Introduces Recurring Buy to Help Users Ride Out Crypto Market Swings
Published on 12/05/2025 at 13:00, 1 hour 51 minutes ago Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 08:45, 6 hours 6 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 20 hours 51 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 21 hours 6 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 21 hours 6 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 7 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
